Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (Menquadfi)
Meningococcal (Groups A, C, Y, W) Conjugate Vaccine is an FDA-licensed reference biologic from Sanofi Pasteur Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2020
Reference approved
Reference product
Menquadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine
Sanofi Pasteur Inc.
- Approved
- Apr 23, 2020
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Meningococcal (Groups A, C, Y, W) Conjugate Vaccine, in chronological order.
First licensure
Date Meningococcal (Groups A, C, Y, W) Conjugate Vaccine was first licensed by the FDA.
6 yr 2 mo ago
Reference approval
Approval date of the reference Meningococcal (Groups A, C, Y, W) Conjugate Vaccine product.
6 yr 2 mo ago
Reference exclusivity ends
12-year reference-product exclusivity under the BPCIA.
in 6 yr
Frequently asked questions
Are there biosimilars approved for Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (Menquadfi)?
No 351(k) biosimilars or interchangeable biosimilars referencing Meningococcal (Groups A, C, Y, W) Conjugate Vaccine are listed in the FDA Purple Book yet.
When does Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (Menquadfi) lose reference-product exclusivity?
Meningococcal (Groups A, C, Y, W) Conjugate Vaccine's 12-year reference-product exclusivity under the BPCIA is listed in the FDA Purple Book as ending April 23, 2032.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.